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Proliferative vitreoretinopathy (PVR) is a blinding dis-
ease associated with rhegmatogenous retinal detach-
ment, for which there is no satisfactory treatment.
Surgery helps in many cases, but, to our knowledge,
there are no pharmacological approaches to reduce
PVR risk. We report that suppressing expression
of p53 was a required event in two assays of PVR
(namely, platelet-derived growth factor receptor
–mediated contraction of cells in a collagen gel and
retinal detachment in an animal model of PVR). Fur-
thermore, preventing the decline in the level of p53
with agents such as Nutlin-3 protected from retinal de-
tachment, which is themost vision-compromising com-
ponent of PVR. Finally, Nutlin-3 may be effective in the
clinical setting because it prevented human PVR vitre-
ous-induced contraction of cells isolated from a patient
PVR membrane. These studies identify Nutlin-3 as a po-
tential PVR prophylaxis. (Am J Pathol 2012, 181:866–874;
http://dx.doi.org/10.1016/j.ajpath.2012.05.036)
Proliferative vitreoretinopathy (PVR) is a blinding disease
that afflicts 5% to 11% of patients who undergo surgery to
correct a rhegmatogenous retinal detachment1; there are
between 1700 and 3700 cases of PVR in the United
States annually.2,3 The treatment for PVR is repeat sur-
gery,4 which is anatomically successful in only 60% to
80% of cases,5,6 and the procedure carries the risk of
recurrence.7–12 Efforts to identify nonsurgical (ie, phar-
macological) approaches to treat PVR have not been
866successful.13–15 Thus, there is a an immediate need for
new therapy options for individuals who are afflicted by
this blinding disease.
The full-thickness retinal break (eg, tears and holes) that
is quintessential to rhegmatogenous retinal detachment re-
sults in exposure of cells to vitreous, a rich source of growth
factors and cytokines.16 These cells migrate into vitreous,
proliferate, and synthesize extracellular matrix proteins.1
This series of events culminates in the formation of a retina-
associated membrane, which contracts and thereby
causes retinal detachment and vision loss.17
Although cells (retinal pigment epithelial cells, glial
cells, and fibroblasts18–20) in PVR membranes express a
plethora of cell surface receptors, the platelet-derived
growth factor (PDGF) receptor  (PDGFR) is essential
for experimental PVR, and is associated with clinical
PVR.21–23 The surprisingly prominent role of PDGFR in
PVR appears to be related to the fact that it can be
engaged by a wide spectrum of vitreal agents, which
activate it indirectly and thereby trigger a signature set of
signaling events that include suppression of p53.24–26
Various forms of cellular stress increase expression
and activate p53, a tetrameric transcription factor, and
thereby trigger the p53 pathway, which leads to cell cycle
arrest, apoptosis, and/or senescence.27 The finding that
p53 and/or the p53 pathway is mutated in approximately
50% of solid tumors28 has motivated the development of
pharmacological agents that stimulate the p53 pathway.
For instance, the small molecule, Nutlin-3, activates the
p53 pathway by preventing p53 from interacting with
murine double min 2 (Mdm2), also called Hdm2 in hu-
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AJP September 2012, Vol. 181, No. 3mans,29 which reduces the level of p53 by a variety of
mechanisms.30–32 Nutlin-3 (RG7112/RO5045337) is in
clinical trials for certain tumors in which the Hdm2/p53
pathway is intact.33 Furthermore, ophthalmic formulation
of Nutlin-3 has been developed.34
The two goals of this study were as follows: i) to test if
the previously noted correlation between the PDGFR-
mediated decline in the level of p53 and the development
of PVR was causally related and ii) to test if Nutlin-3–
mediated stabilization of p53 is a potential approach to
prevent PVR.
Materials and Methods
Major Reagents and Cell Culture
The phospho-Y742 PDGFR antibody was raised against
the phospho-peptide KQADTTQpYVPMLDMK.35 The Ras
GTP-activating protein (RasGAP) antibody was crude rabbit
antiserum against a GST fusion protein including the SH2-
SH3-SH2 region of the human RasGAP.36 Antibodies
against PDGFR, phospho-Akt (S473), Akt, and p53 were
obtained from Cell Signaling Technology (Beverly, MA).
Secondary antibodies (horseradish peroxidase–conju-
gated goat anti-rabbit IgG and goat anti-mouse IgG) were
obtained from Santa Cruz Biotechnology (Santa Cruz,
CA). Enhanced chemiluminescent substrate for detection
of horseradish peroxidase was from Pierce Protein Re-
search Products (Rockford, IL). An ApoAlert annexin
V–fluorescein isothiocyanate apoptosis kit and an in situ
-galactosidase assay kit were obtained from Clontech
Laboratories, Inc. (Mountain View, CA) and Agilent Tech-
nologies (Santa Clara, CA), respectively. Nutlin-3 was ob-
tained from Cayman Chemical (Ann Arbor, MI). Normal
rabbit vitreous (RV) was prepared from frozen rabbit eye-
balls, as previously described.24 The level of PDGFs in RV
is either very low or lower than the level of detection.37,38
RPEM cells are retinal pigment epithelial (RPE) cells
derived from a human epiretinal membrane, as previ-
ously described.39 Ethics approval was obtained from
the Clinical Ethics Research Board (University of British
Columbia, Vancouver, BC, Canada) and the Capital
Health Authority Research Ethics Board (Halifax, NS) be-
fore retaining patient vitreous and/or PVR membranes
that would have been otherwise discarded. Primary rab-
bit conjunctival fibroblasts (RCFs) were obtained and
cultured as previously described.40 RCFs that stably
expressed the short hairpin RNA (shRNA)–targeting vec-
tor specific for green fluorescent protein (GFP), PDGFR,
p53, or PDGFR/p53 were designated shGFP,
shPDGFR, shp53, and shPDGFR/p53, respectively. F
cells are immortalized mouse embryo fibroblasts derived
from PDGFR knockout mice that do not express either of
the two PDGFR genes; F and F cells are F cells in
which PDGFR or PDGFR has been re-expressed.21
Knockdown of PDGFR and p53
Oligos (5=-GCCAGCTCTTATTACCCTCTA-3= for PDGFR,
5=-CGGGCGTAAACGCTTCGAGAT-3= for p53, and 5=-
ACAACAGCCACAACGTCTATA-3= for GFP) in a hairpin-pLKO.1 retroviral vector, the packaging plasmid (pCMV-
dR8.91), the envelope plasmid (VSV-G/pMD2.G), and
293T packaging cells were from Dana-Farber Cancer
Institute/Harvard Medical School (Boston, MA). The
shRNA lentiviruses were prepared as previously de-
scribed.26 The viruses were used to infect RCF cells.
Successfully infected cells were selected on the basis of
their ability to proliferate in media containing puromycin
(1 g/mL). The resulting cells were characterized by us-
ing Western blot analysis using antibodies against
PDGFR, p53, and RasGAP (loading control).
Western Blot Analysis
Cells were grown to 90% confluence in serum-containing
medium, and then incubated for 24 hours in medium
without serum. Cells were stimulated (as detailed for
each experiment), washed twice with ice-cold PBS, and
lysed in extraction buffer (10 mmol/L Tris-HCl, pH 7.4; 5
mmol/L EDTA; 50 mmol/L NaCl; 50 mmol/L NaF; 1%
Triton X-100; 20 g/mL aprotinin; 2 mmol/L Na3VO4; and
1 mmol/L phenylmethylsulfonyl fluoride). Lysates were
clarified by centrifugation at 13,000  g, 4°C for 15 min-
utes. Equal amounts of protein were separated by 10%
SDS-PAGE, transferred to PVDF membranes, and then
subjected to Western blot analysis using indicated anti-
bodies. The signal intensity was determined by densitom-
etry and analyzed with Quantity One software (Bio-Rad,
Hercules, CA).
Collagen I Contraction Assay
Cells were trypsinized, washed, and resuspended in 1.5
mg/mL of neutralized collagen I (INAMED, Fremont, CA)
(pH 7.2) at a density of 1  106 cells/mL for RPEM or 5 
104 cells/mL for RCFs. The mixture was fractionated into
wells of a 24-well plate that had been preincubated over-
night with 5 mg/mL bovine serum albumin in PBS. The
collagen solution was solidified by incubating at 37°C for
90 minutes, and overlaid with medium containing the
desired agents. The media were replaced every day, and
the gel diameter was measured on day 3. The gel area
was calculated using the formula r2, where r is the
radius of the gel.
Proliferation and Apoptosis Assays
Proliferation and apoptosis were assayed as previously
described.24 Briefly, RCFs were seeded into 24-well
plates at a density of 50,000 cells per well in Dulbecco’s
modified Eagle’s medium (DMEM) plus 10% fetal bovine
serum (FBS). After 6 hours, the cells had attached; the
medium was aspirated; the cells were rinsed twice with
PBS; and the cells were cultured in serum-free DMEM
with or without RV (1:3 dilution). The media were replaced
every day. On day 3, the cells were counted in a hemo-
cytometer. At least three independent experiments were
performed.
To monitor apoptosis, RCFs were seeded into 6-cm
dishes at a density of 1 105 cells per dish in DMEM plus
10% FBS. After the cells had attached to the dishes, they
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day 3, the cells were harvested and stained with fluores-
cein isothiocyanate–conjugated annexin V and pro-
pidium iodide, according to the instructions provided with
the apoptosis kit (BD Biosciences, Palo Alto, CA). The
cells were analyzed by flow cytometry in Coulter Beck-
man XL (Caguas, Puerto Rico). At least three indepen-
dent experiments were performed.
Senescence Assay
RCF cells were plated into a 12-well plate (10,000 cells
per well) in DMEM (high glucose) supplemented with
10% FBS. After 6 hours, the medium was replaced with
DMEM with or without RV (1:3 dilution) and replenished
every 24 hours. On day 3, the -galactosidase activity
was assessed according to the manufacturer’s instruc-
tions provided with the in situ -galactosidase assay kit.
Rabbit Model for PVR
PVR was induced in Dutch Belted rabbits, obtained from
Covance (Denver, PA), as previously described.25
Briefly, a gas vitrectomy was performed by injecting 0.1
mL of perfluoropropane (C3F8) (Alcon, Fort Worth, TX)
into vitreous. One week later, the right eye of rabbits was
injected in one of two ways. For the experiment injecting
RCFs expressing shRNAs, 0.1 mL of DMEM containing
1  105 RCFs that were modified as outlined in Figure 3
were injected, along with 0.1 mL of rabbit platelet-rich
plasma. For the Nutlin-3 experiment, all rabbits were in-
jected with 0.1 mL of DMEM containing 1  105 unmod-
ified RCFs and 0.1 mL rabbit platelet-rich plasma, and
either not injected a third time or injected with vehicle or
0.1 mL of 200 mol/L Nutlin-3. The vehicle or Nutlin-3
injection was repeated on days 3 and 5. The retinal status
was evaluated with an indirect ophthalmoscope fitted
with a 30 D fundus lens on days 1, 3, 5, 7, 14, 21, and
28. PVR was graded according to the Fastenberg scale
of classification41: stage 0, no disease; stage 1, epiretinal
membrane; stage 2, vitreoretinal traction without retinal
detachment; stage 3, localized retinal detachment (one
to two quadrants); stage 4, extensive retinal detachment
(two to four quadrants without complete detachment);
and stage 5, complete retinal detachment. On day 28,
animals were sacrificed, and eyes were enucleated and
frozen at80°C. All surgical procedures were performed
under aseptic conditions and pursuant to the Association
for Research in Vision and Ophthalmology Statement for
the Use of Animals in Ophthalmic and Vision Research.
The protocol for the use of animals was approved by the
Schepens Animal Care and Use Committee.
Immunohistochemical Data
Rabbit eyeballs were fixed in 10% formalin for 48 hours
and embedded in paraffin after dehydration. Subse-
quently, paraffin sections (4 m thick) were prepared,
dewaxed in xylene, and rehydrated in ethanol, diluted
ethanol, and deionized water. Antigen retrieval was per-
formed by boiling the slides for 20 minutes in a citrate-based buffer (Vector Laboratories Inc., Burlingame, CA).
The endogenous peroxidase activity was blocked by in-
cubation with 1% H2O2 in methanol for 10 minutes, and
the endogenous avidin and biotin binding sites were
blocked by incubation with avidin and biotin blocking
buffers (Vector Laboratories Inc.). The resulting sections
were first incubated in blocking buffer containing 3%
goat serum, and then in primary antibody [diluted 1:200
in blocking buffer, anti-p53, from Abcam (Cambridge,
MA)] overnight at 4°C. Incubation with secondary anti-
body (biotinylated goat anti-mouse; Abcam) was for 1
hour at room temperature. Finally, the ABC reagent (Vec-
tor Laboratories Inc.) was added for 45 minutes, and
the sections were stained with 3,3=-diaminobenzidine
(Thermo Scientific, Rockford, IL). The sections were ob-
served and photographed under a microscope.
Statistics
The experimental data were analyzed using an unpaired
t-test and one-way analysis of variance and/or post tests.
P  0.05 was considered statistically significant.
Results
Suppressing p53 Is Essential for RV-Induced
Contraction and Retinal Detachment
RV contained a variety of non-PDGFs that indirectly acti-
vated PDGFR and thereby chronically stimulated Akt,26
which phosphorylated and activated Mdm2,42 which me-
diated a decline in the level of p53.43–45 Nutlin-3 antag-
onized the interaction of Mdm2 and p53, and thereby
prevented Mdm2-mediated reduction of p53.29 Because
of these properties, we considered whether Nutlin-3
would prevent RV-mediated reduction in the level of p53,
prevent contraction of cells in collagen gels, and protect
rabbits from developing PVR. We chose primary RCFs for
these studies because they robustly contracted collagen
gels and induced PVR.
Nutlin-3 effectively blocked the RV-mediated decline in
the level of p53 and contraction of collagen gels (Figure
1, A and B). As expected, it had no effect on RV-induced
phosphorylation of PDGFR or activation of Akt (Figure
1A), events that were upstream of the known action of
Nutlin-3. The minimum dose to prevent the RV-induced
reduction of p53 was 2 mmol (see Supplemental Figure
S1A at http://ajp.amjpathol.org), whereas the maximum
tolerated dose was 30 mmol (see Supplemental Figure
S1B at http://ajp.amjpathol.org). Moreover, multiple intra-
vitreal injections of Nutlin-3 of up to 20 mmol did not
produce overt signs of retinal toxicity (see Supplemen-
tal Figure S2 at http://ajp.amjpathol.org and data not
shown). These results set the stage to test if Nutlin-3 could
prevent retinal detachment in an animal model of PVR.
As shown in Figure 2, 100% of the animals in both
control groups (uninjected, open circles; or injected with
vehicle, filled circles) developed complete retinal detach-
ment (stage 5) by day 28. In contrast, 0% of the Nutlin-
3–treated animals (Figure 2A) succumbed to even partial
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membranes (stage 1 and 2 in Figure 2A; see also Sup-
plemental Figure S2 at http://ajp.amjpathol.org). More im-
portant, the p53 level was higher in epiretinal membranes
isolated from Nutlin-3–injected animals compared with
vehicle-injected controls (Figure 2B). These observations
Figure 2. Nutlin-3 prevents retinal detachment and elevates p53 in epiretinal
PVR, as described in Materials and Methods. The indicated rabbits receive n
mol/L) on days 0, 2, and 4. PVR was graded according to the Fastenberg
vitreoretinal traction without retinal detachment; stage 3, localized retinal de
without complete detachment); stage 5, complete retinal detachment. The
asterisk denotes a statistically significant difference. B: Nutlin-3 enhances e
the eyes are enucleated and paraffin sections of whole eyes are subjected
and right panels: A Nutlin-3–injected animal. Middle panel: A rabbit treated wit
panel: Stained with non–immune IgG. Scale bar  50 m.indicated that Nutlin-3 treatment maintained a high level
of p53 expression in cells of the epiretinal membrane and
prevented retinal detachment.
A molecular approach to assess the importance of
reducing p53 for RV-mediated contraction and retinal
detachment led to a similar conclusion. The overall strat-
Figure 1. Nutlin-3 prevents both the RV-induced
decline in the level of p53 and contraction. A: The
impact of Nutlin-3 on RV-mediated signaling
events. RCFs are pretreated with either Nutlin-3 (10
mol/L) or vehicle for 30 minutes and then ex-
posed to either RV (diluted 1:3 in DMEM) or
DMEM for 2 hours. The resulting cell lysates are
subjected to Western blot analysis using the indi-
cated antibodies. The numbers are a ratio of p-
PDGFR/PDGFR, p-Akt/Akt, or p53/RasGAP.
The data presented are representative of three in-
dependent experiments. B: The impact of Nutlin-3
on RV-mediated contraction. RCFs are subjected to
the collagen contraction assay. Nutlin-3 (10
mol/L) or vehicle was added as indicated. The
data are subjected to a paired t-test. The asterisk
indicates a statistically significant difference.
nes. A: The impact of Nutlin-3 on experimental PVR. RCFs are used to induce
ional injections (none) or 0.1-mL injections of either vehicle or Nutlin-3 (20
classification 41: stage 0, no disease; stage 1, epiretinal membrane; stage 2,
t (1 to 2 quadrants); stage 4, extensive retinal detachment (2 to 4 quadrants
subjected to an unpaired t-test or a one-way analysis of variance test. The
n of p53 in epiretinal membranes. At the end of the experiment (day 28),
HC. Arrows, epiretinal membrane; arrowheads, retina; brown, p53. Leftmembra
o addit
scale of
tachmen
data are
xpressio
to p53 Ih vehicle. Left and middle panels: Stained with the p53 antibody. Right
enotes
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tial of RCFs by silencing the expression of PDGFR, and
then to test if it could be rescued by silencing the expres-
sion of p53. Lentiviral-mediated delivery of shRNAs di-
rected toward either PDGFR or p53 suppressed expres-
sion by at least 80% (Figure 3A). As shown in Figure 3B,
RV-mediated suppression of p53 in shPDGFR cells was
substantially reduced, although not completely elimi-
nated. Similarly, RV-induced contraction of cells was
largely, although not completely, diminished in shPDGFR
cells (Figure 3C).
To investigate whether the incomplete suppression of
RV-mediated contraction was due to the residual expres-
sion of PDGFR, we tested the efficacy of imatinib to
interfere with RV-induced contraction. Imatinib com-
pletely blocked RV-induced contraction in shGFP cells
(see Supplemental Figure S3A at http://ajp.amjpathol.
org), which indicated that one of the imatinib targets (abl
or c-kit PDGFR and PDGFR46) was essential. Our pre-
viously characterized panel of cells that did or did not ex-
press PDGFRs21 provided the opportunity to identify the
relevant imatinib target. F cells, which were immortalized
Figure 3. Molecularly suppressing expression of p53 rescues the ability of
Lentiviruses are used to stably express shRNAs directed against GFP, PDGF
analysis using the indicated antibodies. The signal intensity is quantified a
representative of two independent experiments. B: Expression of PDGFR p
to vitreous (diluted 1:3 in DMEM) from normal rabbits (RV) for 2 hours and
antibodies. The signal intensity is quantified, and the data presented are repre
The asterisk denotes a statistically significant difference. C: RV induces con
of p53. The cells in A are subjected to a collagen contraction assay. RV (dilute
the experiment is terminated on day 3. The panel below the bar graph show
a single experiment. The data are subjected to a paired t-test. The asterisk d
three independent experiments. NS, not significant.fibroblasts from mice lacking both PDGFR genes (but har-
boring all other imatinib targets), contracted weakly to
RV, and this response was unaffected by imatinib (see
Supplemental Figure S3B at http://ajp.amjpathol.org). Ex-
pressing PDGFR in these cells did not improve RV-
induced contraction or generate sensitivity to imatinib
(see Supplemental Figure S3B at http://ajp.amjpathol.
org). Finally, expression of PDGFR improved this RV-
stimulated response, which was erased by imatinib (see
Supplemental Figure S3B at http://ajp.amjpathol.org).
These observations indicated that PDGFR was the rel-
evant target of imatinib, and suggested that the modest
RV-induced contraction seen in shPDGFR cells (Figure
3C) was because of residual expression of PDGFR.
As expected from previous studies assessing the im-
portance of PDGFR for experimental PVR,21,25,47 there
was a significantly statistic reduction in the PVR potential
of shPDGFR cells (Figure 4). shPDGFR cells failed to
induce retinal detachment, although they retained their
ability to form membranes, which exerted traction of the
retina (Figure 4). Molecularly suppressing p53 in
shPDGFR cells fully restored their ability to induce reti-
-deficient cells to contract. A: Western blot analysis of knockdown RCFs.
53 in primary RCFs. The resulting cell lysates are subjected to Western blot
ressed as a ratio of the loading control (RasGAP). The data presented are
s RV-mediated suppression of p53. The cells in A are left resting or exposed
d total cell lysates are subjected to Western blot analysis with the indicated
e of three independent experiments. The data are subjected to a paired t-test.
of RCF-loaded collagen gels, which requires PDGFR-mediated suppression
DMEM) is added on top of the gels on day 0 and replenished every 24 hours;
graphs of representative gels; the data in the bar graph are triplicates within
a statistically significant difference. The data presented are representative of
Figure 4. Molecularly suppressing expression
of p53 restores the ability of PDGFR-deficient
cells to induce retinal detachment. The cells de-
scribed in the legend to Figure 3A are compared
for their PVR potential in a rabbit model of this
disease. Inset: The type of lenti-shRNA used to
modify the cells. PVR is induced as described in
Materials and Methods. Each symbol represents
the response of an individual rabbit on the indi-
cated day. The data are subjected to an unpaired
t-test or a one-way analysis of variance. The
asterisk denotes a statistically significant differ-
ence.PDGFR
R, or p
nd exp
otentiate
lysed, an
sentativ
traction
d 1:3 in
s photo
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tal approaches indicated that reducing the level of p53
was essential for RV-mediated contraction and retinal
detachment in an animal model of PVR.
PDGFR Does More than Reduce p53 to
Promote Contraction
To assess if reducing p53 was the only PDGFR-medi-
Figure 5. The importance of PDGFR and suppression of p53 for RV-
dependent cell proliferation and protection from apoptosis and senescence.
A: RCFs (shGFP, shPDGFR, shPDGFR/shp53, and shp53) are seeded into
a 24-well plate at a density of 5  104 cells per well in DMEM plus 10% FBS.
Six hours after the cells attach, the medium is changed to either 0.5-mL
DMEM or rabbit vitreous (diluted 1:3 in DMEM). The media are replaced
every day. The cells are counted with a hemocytometer on day 3. The
mean  SD of three independent experiments is shown. *P  0.05 using a
paired t-test. B: The RCFs in A are seeded into 60-mm dishes at a density of
100,000 cells per dish in DMEM plus 10% FBS. Six hours after the cells attach,
the medium is changed to either 3-mL DMEM or rabbit vitreous (diluted 1:3
in DMEM). The media are replaced every day. On day 3, the cells are stained
with fluorescein isothiocyanate–conjugated annexin V and propidium iodide
(PI) in an apoptosis assay kit by following the manufacturer’s instructions.
Cells that are stained with annexin V and/or PI are detected and quantified
by flow cytometry in Coulter Beckman XL. The mean  SD of three inde-
pendent experiments is shown. C: The RCFs in A are seeded into a 12-well
plate at a density of 10,000 cells per well in DMEM plus 10% FBS. Six hours
after the cells attach, the medium is changed to either 1-mL DMEM or rabbit
vitreous (diluted 1:3 in DMEM). The media are replaced every day. On day
3, the -galactosidase activity is measured as outlined in the manufacturer’s
instructions. Both stained and unstained cells are counted and photographed
under an inverted microscope. The mean  SD of three independent exper-
iments is shown. *P  0.05 using a paired t-test. NS, not significant. Scale
bar  50 m.ated event required for contraction in response to RV, wecompared this outcome in shGFP and shp53 cells. If it
was the only event, then the contraction of shp53 cells
would be RV independent. As shown in Supplemental
Figure S4 (available at http://ajp.amjpathol.org), this
was not the case. Although basal contraction of shp53
cells was enhanced, they responded well to RV. These
observations indicated that PDGFR did more than
reduce the level of p53 to mediate RV-dependent con-
traction.
We asked the same question for three additional cel-
lular responses associated with PVR: proliferation, pro-
tection from apoptosis and senescence. Just like con-
traction, proliferation of shp53 cells was responsive to RV
(Figure 5A). In contrast, protection from apoptosis and
senescence were fully engaged in unstimulated cells and
RV did not further enhance these responses (Figure 5, B
and C). These findings indicated that reducing p53 was
sufficient to trigger some of the RV-stimulated cellular re-
sponses that were associated with PVR (protection from
apoptosis and senescence), whereas contraction and pro-
liferation required an event(s) in addition to reducing the
level of p53 (Figure 6). The identity of the signaling en-
zymes responsible for mediating this event(s) is under
investigation.
Residual expression of PDGFR in shPDGFR cells
provided an opportunity to compare cellular responses
associated with PVR for their dependence on the level of
expression of PDGFR. In shPDGFR cells, RV was still
able to promote contraction (Figure 3C), proliferation
(Figure 5A) and survival (Figure 5B), however to a much
lesser extent than in control cells. In contrast, RV failed to
protect shPDGFR cells from senescence (Figure 5C). We
conclude that protection from senescence required a
higher level of PDGFR expression than the other three
cellular responses.
Relevance to Clinical PVR
To begin to assess the clinical relevance of these find-
ings, we considered the impact of Nutlin-3 on human
vitreous (HV)–mediated signaling events and contraction
Figure 6. RV-engaged PDGFR triggers two signaling pathways that drive
cellular response intrinsic to PVR: signaling pathway 1, leading to a reduction
in the level of p53; this is sufficient for protection from apoptosis and
senescence. Contraction and proliferation require an additional set of signal-
ing events that constitute pathway 2. ROS, reactive oxygen species; SFK, src
family kinases.
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shown in Figure 7A, Nutlin-3 prevented the precipitous
decline in the level of p53 observed in HV-treated control
cells, without affecting upstream signaling events. Fur-
thermore, Nutlin-3 inhibited HV-stimulated contraction
of RPE-containing collagen gels (Figure 7B). In addi-
tion, p53 was undetectable in epiretinal membranes
from patients with PVR (see Supplemental Figure S5 at
http://ajp.amjpathol.org). These findings indicated that
Nutlin-3 had the potential to protect patients from devel-
oping PVR.
Discussion
We report that suppressing the expression of p53 ap-
peared to be a required event in PDGFR-mediated con-
traction of cells in a collagen gel and retinal detachment
in an animal model of PVR. Furthermore, preventing the
decline in the level of p53 with agents such as Nutlin-3
protected from retinal detachment. Finally, Nutlin-3 may
be effective in the clinical setting because it prevented
human PVR vitreous-induced contraction of cells isolated
from a patient PVR membrane.
In the present study, we administered Nutlin-3 in a
series of intravitreal injections. Although this approach
completely prevented retinal detachment, 50% of the
rabbits developed vitreal traction (stage 2) (Figure 2A).
Because the last injection of Nutlin-3 was 23 days before
the end of the experiment, the level of Nutlin-3 may have
decreased to lower than the therapeutic range. The re-
cently developed ocular formulation of Nutlin-3, which
can be administered as a subconjunctival injection,34
may be a more effective approach to achieve Nutlin-3–
mediated PVR prophylaxis.
Nutlin-3 treatment effectively prevented retinal detach-
ment, and also slowed formation of membranes (stage 1)
(Figure 2A), both of which are of clinical benefit. We were
intrigued that membranes were able to form in Nutlin-3
animals because Nutlin-3 activates the p53 pathway,29
which counters cellular events that are intrinsic to mem-
brane formation, such as proliferation and survival.48
However, this observation is consistent with reports that
elevating p53 does not always cause apoptosis and/or
cell cycle arrest.49–51 For instance, p53 is transientlyelevated in mitotic cells of normal tissue in healthy ani-
mals, and fails to engage the p53 pathway because p53
is held in check by post-translational modifications.52
Additional studies are required to assess if this mecha-
nism explains why membranes form in Nutlin-3–treated
animals.
These studies reveal that cellular responses associ-
ated with PVR do not have the same requirements. Con-
traction and proliferation require a decline in the level of
p53 and a second PDGFR-mediated event (s), whereas
protection from apoptosis and senescence proceed
when only p53 is suppressed (Figure 6).
Epiretinal membranes formed in rabbits injected with
cells that were unable to suppress p53 efficiently
(shPDGFR), which was required for optimal RV-medi-
ated proliferation and viability, cellular events that are
thought to be essential for membrane formation. Previous
investigators have found that proliferation-incompetent
cells induce PVR, provided that they are injected at a
sufficiently high level.53 Thus, membranes may have
formed in rabbits injected with shPDGFR cells because
enough of them were injected.
Both molecular and pharmacological approaches in-
dicate that reducing the level of p53 was permissive for
retinal detachment, a process that involves contraction of
the retina-associated membrane. A simple explanation
for this phenomenon is that p53 suppresses the expres-
sion of genes that are required for retinal detachment. For
instance, p53 may inhibit production of those extracellu-
lar matrix proteins that are required for contraction of the
membrane.54 However, such an explanation appears in-
adequate for the in vitro contraction assays, which con-
tained ample extracellular matrix proteins that are con-
ducive for contraction. Perhaps p53 down-regulates
expression of integrins, such as 1,55 whose interaction
with extracellular matrix proteins is essential for contrac-
tion. Alternatively, there may be a connection to epithelial
cell membrane protein and focal adhesion kinase, which
are essential for contraction of collagen gels and strongly
implicated in PVR.56–60 Identifying the p53-governed
genes that are essential for retinal detachment is an on-
going area of investigation.
Finally, just as p53 suppresses cell cycle progres-
Figure 7. p53 Attenuates HV-driven collagen
gel contraction. A: The impact of Nutlin-3 on
HV-mediated signaling events. The experiment
is the same as in Figure 3A, except RPE cells
from a patient epiretinal membrane are used in
place of RCF, and HV (a pool of vitreous from
five patients with PVR, diluted 1:3 in DMEM) is
used in place of RV. The data presented are
representative of three independent experi-
ments. B: The impact of Nutlin-3 on HV-medi-
ated contraction. The experiment is the same as
in Figure 3B, with the modification noted in
Figure 5A. The data are subjected to a paired
t-test. The asterisk denotes a statistically signif-
icant difference. The data shown are represen-
tative of three independent experiments.sion,61 our findings indicate that p53 is the checkpoint of
p53 Antagonizes PVR 873
AJP September 2012, Vol. 181, No. 3retinal detachment. In contrast to genetic lesions of the
p53 pathway that are present in approximately 50% of
solid tumors,28 it appears that epigenetic, environmental
factors that result in noncanonical activation of PDGFR
drive p53-dependent blinding diseases, such as PVR.
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